Kymera Therapeutics, Inc.
KYMR
$81.21
$1.612.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.84% | -75.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.84% | -75.91% | |||
| Cost of Revenue | 13.14% | -5.48% | |||
| Gross Profit | -13.50% | -6.60% | |||
| SG&A Expenses | -2.31% | -1.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.21% | -4.79% | |||
| Operating Income | -10.41% | -4.86% | |||
| Income Before Tax | -5.85% | -7.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -5.85% | -7.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -5.85% | -7.26% | |||
| EBIT | -10.41% | -4.86% | |||
| EBITDA | -13.57% | -3.18% | |||
| EPS Basic | -2.77% | 1.16% | |||
| Normalized Basic EPS | -7.83% | 5.80% | |||
| EPS Diluted | -2.77% | 1.16% | |||
| Normalized Diluted EPS | -7.83% | 5.80% | |||
| Average Basic Shares Outstanding | 2.99% | 8.52% | |||
| Average Diluted Shares Outstanding | 2.99% | 8.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||